Q3056502 (Q3056502): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
(Created claim: summary (P836): The overall objective of the HYCOR project is to facilitate implementation of the Smart Specialisation Strategy (3S) priorities in Latvia, thus developing the research potential of the country, strengthening the knowledge-based society and promoting the competitive advantage of the economy and strengthening international cooperation in the field of research.Special objective is to promote the concept of expiratory volatile marker in colorectal c...) |
||||||||||||||
| Property / summary | |||||||||||||||
The overall objective of the HYCOR project is to facilitate implementation of the Smart Specialisation Strategy (3S) priorities in Latvia, thus developing the research potential of the country, strengthening the knowledge-based society and promoting the competitive advantage of the economy and strengthening international cooperation in the field of research.Special objective is to promote the concept of expiratory volatile marker in colorectal cancer (CRC) screening by promoting the development of a new hybrid analyser for this purpose. The rationale for the project is based on the group’s previous experience as well as new technological advances in the determination of volatile organic compounds (VOC) in human exhalation to detect cancer. The hybrid analyser concept is expected to benefit from the pooling of metal oxide (MOX) and infrared spectrum (IS) sensors. This study will be the first to address this concept globally in the definition of the CRC. In addition, traditional methods, in particular gas chromatography together with mass spectrometry (GC-MS), will be used to explore the biological relevance of VOCs emitted from cancer tissues, which will help to further develop a hybrid capture approach.Four specific research objectives have been set to achieve the project’s objectives:1 Specific Support Objective (SAM1). Identify VOCs emitted by CRC tissues and compare them with VOC emitted by non-cancerous tissues (ex vivo surgical material) using GC-MS.2 Specific Support Objective (SAM2). Identify VOCs that differ between CRC patients and control patients in exhalation (using GC-MS) and compare expiratory chemical signage of CRC patients with cancer tissue chemical signage.3 Specific Support Objective (SAM3). Assess the performance of a set of sensors in a hybrid analyser and the performance of specific sensors for the determination of CRCs; Develop and validate a mathematical model for the determination of CRV.4 specific support objective (SAM4). Validate the hybrid analyser at real-time CRC screening sites, i.e. compared to the conventional CRC screening method – faecal occult blood detection.The project will be realised by implementing a total of 6 interconnected work packages (DPs), each of which will be divided into detailed research tasks: OP1. Significant preparatory work.DP2. Identification of specific VOC in CRC tissue surgical material.DP3. Identification of specific VOCs in exhalation of CRC patients based on GC-MS results.DP4. Expiratory VOC assay and primary validation study with hybrid analyser.DP5. Secondary validation study at general CRC screening sites.DP6. Knowledge sharing, communication and dissemination.Scientific results of this project will provide new knowledge about the possible use of a hybrid expiratory analyser in CRC screening, possibly replacing the current phases of screening in population screening programmes. Although screening programmes are currently available in most European Union (EU) countries, the tests currently used are still not ideal. Therefore, the obtained results would be important for clinical practice in Latvia or globally – in countries with average or high CRC burden.It is planned to do this in the industrial research project (TRL 3-4), and the planned activities are not related to commercial activities. According to the classification of the Organisation for Economic Cooperation and Development (OECD), the project complies with the health science (3.3, Research and Development Classification, Frascati Manual, 2015).As a result of the study, a new medical technology with high added value will be developed, thus contributing to the implementation of the 1st growth priority of the Latvian RIS3 strategy, especially priority: “Knowledge-intensive medicine, including biomedicine, medical technologies.”The aim of the project is to develop a fundamentally new approach to cancer detection through breath analysis. A mathematical model will be developed based on VOC results; The hybrid analyser will be validated. It is planned to prepare and publish 3 original scientific publications in peer-reviewed journals, 2 of them – in journals with a citation rate > 50 % of the average in the respective field. The results are expected to be distributed in 5 theses. This project will employ at least 2 students, including 1 doctoral students; After the completion of the project, 2 young scientists will be saved.The project will be implemented under the guidance of the University of Latvia (LU) in partnership with Liepaja Regional Hospital (hospital).The total budget of the project is EUR 540540.00, of which 92.5 % – EUR 499999.50 is state funding (including public funding from ERDF – 82.29 % EUR 444810.37, Latvian government – 10.21 % – EUR 55189.13) and 7.50 % EUR 40540.50 from the private sector. (English) | |||||||||||||||
| Property / summary: The overall objective of the HYCOR project is to facilitate implementation of the Smart Specialisation Strategy (3S) priorities in Latvia, thus developing the research potential of the country, strengthening the knowledge-based society and promoting the competitive advantage of the economy and strengthening international cooperation in the field of research.Special objective is to promote the concept of expiratory volatile marker in colorectal cancer (CRC) screening by promoting the development of a new hybrid analyser for this purpose. The rationale for the project is based on the group’s previous experience as well as new technological advances in the determination of volatile organic compounds (VOC) in human exhalation to detect cancer. The hybrid analyser concept is expected to benefit from the pooling of metal oxide (MOX) and infrared spectrum (IS) sensors. This study will be the first to address this concept globally in the definition of the CRC. In addition, traditional methods, in particular gas chromatography together with mass spectrometry (GC-MS), will be used to explore the biological relevance of VOCs emitted from cancer tissues, which will help to further develop a hybrid capture approach.Four specific research objectives have been set to achieve the project’s objectives:1 Specific Support Objective (SAM1). Identify VOCs emitted by CRC tissues and compare them with VOC emitted by non-cancerous tissues (ex vivo surgical material) using GC-MS.2 Specific Support Objective (SAM2). Identify VOCs that differ between CRC patients and control patients in exhalation (using GC-MS) and compare expiratory chemical signage of CRC patients with cancer tissue chemical signage.3 Specific Support Objective (SAM3). Assess the performance of a set of sensors in a hybrid analyser and the performance of specific sensors for the determination of CRCs; Develop and validate a mathematical model for the determination of CRV.4 specific support objective (SAM4). Validate the hybrid analyser at real-time CRC screening sites, i.e. compared to the conventional CRC screening method – faecal occult blood detection.The project will be realised by implementing a total of 6 interconnected work packages (DPs), each of which will be divided into detailed research tasks: OP1. Significant preparatory work.DP2. Identification of specific VOC in CRC tissue surgical material.DP3. Identification of specific VOCs in exhalation of CRC patients based on GC-MS results.DP4. Expiratory VOC assay and primary validation study with hybrid analyser.DP5. Secondary validation study at general CRC screening sites.DP6. Knowledge sharing, communication and dissemination.Scientific results of this project will provide new knowledge about the possible use of a hybrid expiratory analyser in CRC screening, possibly replacing the current phases of screening in population screening programmes. Although screening programmes are currently available in most European Union (EU) countries, the tests currently used are still not ideal. Therefore, the obtained results would be important for clinical practice in Latvia or globally – in countries with average or high CRC burden.It is planned to do this in the industrial research project (TRL 3-4), and the planned activities are not related to commercial activities. According to the classification of the Organisation for Economic Cooperation and Development (OECD), the project complies with the health science (3.3, Research and Development Classification, Frascati Manual, 2015).As a result of the study, a new medical technology with high added value will be developed, thus contributing to the implementation of the 1st growth priority of the Latvian RIS3 strategy, especially priority: “Knowledge-intensive medicine, including biomedicine, medical technologies.”The aim of the project is to develop a fundamentally new approach to cancer detection through breath analysis. A mathematical model will be developed based on VOC results; The hybrid analyser will be validated. It is planned to prepare and publish 3 original scientific publications in peer-reviewed journals, 2 of them – in journals with a citation rate > 50 % of the average in the respective field. The results are expected to be distributed in 5 theses. This project will employ at least 2 students, including 1 doctoral students; After the completion of the project, 2 young scientists will be saved.The project will be implemented under the guidance of the University of Latvia (LU) in partnership with Liepaja Regional Hospital (hospital).The total budget of the project is EUR 540540.00, of which 92.5 % – EUR 499999.50 is state funding (including public funding from ERDF – 82.29 % EUR 444810.37, Latvian government – 10.21 % – EUR 55189.13) and 7.50 % EUR 40540.50 from the private sector. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The overall objective of the HYCOR project is to facilitate implementation of the Smart Specialisation Strategy (3S) priorities in Latvia, thus developing the research potential of the country, strengthening the knowledge-based society and promoting the competitive advantage of the economy and strengthening international cooperation in the field of research.Special objective is to promote the concept of expiratory volatile marker in colorectal cancer (CRC) screening by promoting the development of a new hybrid analyser for this purpose. The rationale for the project is based on the group’s previous experience as well as new technological advances in the determination of volatile organic compounds (VOC) in human exhalation to detect cancer. The hybrid analyser concept is expected to benefit from the pooling of metal oxide (MOX) and infrared spectrum (IS) sensors. This study will be the first to address this concept globally in the definition of the CRC. In addition, traditional methods, in particular gas chromatography together with mass spectrometry (GC-MS), will be used to explore the biological relevance of VOCs emitted from cancer tissues, which will help to further develop a hybrid capture approach.Four specific research objectives have been set to achieve the project’s objectives:1 Specific Support Objective (SAM1). Identify VOCs emitted by CRC tissues and compare them with VOC emitted by non-cancerous tissues (ex vivo surgical material) using GC-MS.2 Specific Support Objective (SAM2). Identify VOCs that differ between CRC patients and control patients in exhalation (using GC-MS) and compare expiratory chemical signage of CRC patients with cancer tissue chemical signage.3 Specific Support Objective (SAM3). Assess the performance of a set of sensors in a hybrid analyser and the performance of specific sensors for the determination of CRCs; Develop and validate a mathematical model for the determination of CRV.4 specific support objective (SAM4). Validate the hybrid analyser at real-time CRC screening sites, i.e. compared to the conventional CRC screening method – faecal occult blood detection.The project will be realised by implementing a total of 6 interconnected work packages (DPs), each of which will be divided into detailed research tasks: OP1. Significant preparatory work.DP2. Identification of specific VOC in CRC tissue surgical material.DP3. Identification of specific VOCs in exhalation of CRC patients based on GC-MS results.DP4. Expiratory VOC assay and primary validation study with hybrid analyser.DP5. Secondary validation study at general CRC screening sites.DP6. Knowledge sharing, communication and dissemination.Scientific results of this project will provide new knowledge about the possible use of a hybrid expiratory analyser in CRC screening, possibly replacing the current phases of screening in population screening programmes. Although screening programmes are currently available in most European Union (EU) countries, the tests currently used are still not ideal. Therefore, the obtained results would be important for clinical practice in Latvia or globally – in countries with average or high CRC burden.It is planned to do this in the industrial research project (TRL 3-4), and the planned activities are not related to commercial activities. According to the classification of the Organisation for Economic Cooperation and Development (OECD), the project complies with the health science (3.3, Research and Development Classification, Frascati Manual, 2015).As a result of the study, a new medical technology with high added value will be developed, thus contributing to the implementation of the 1st growth priority of the Latvian RIS3 strategy, especially priority: “Knowledge-intensive medicine, including biomedicine, medical technologies.”The aim of the project is to develop a fundamentally new approach to cancer detection through breath analysis. A mathematical model will be developed based on VOC results; The hybrid analyser will be validated. It is planned to prepare and publish 3 original scientific publications in peer-reviewed journals, 2 of them – in journals with a citation rate > 50 % of the average in the respective field. The results are expected to be distributed in 5 theses. This project will employ at least 2 students, including 1 doctoral students; After the completion of the project, 2 young scientists will be saved.The project will be implemented under the guidance of the University of Latvia (LU) in partnership with Liepaja Regional Hospital (hospital).The total budget of the project is EUR 540540.00, of which 92.5 % – EUR 499999.50 is state funding (including public funding from ERDF – 82.29 % EUR 444810.37, Latvian government – 10.21 % – EUR 55189.13) and 7.50 % EUR 40540.50 from the private sector. (English) / qualifier | |||||||||||||||
point in time: 15 July 2021
| |||||||||||||||
Revision as of 12:35, 15 July 2021
Project Q3056502 in Latvia
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3056502 in Latvia |
Statements
444,810.36 Euro
0 references
540,540.0 Euro
0 references
1 July 2021
0 references
30 November 2023
0 references
LATVIJAS UNIVERSITĀTE
0 references
56°33'10.58"N, 21°5'57.88"E
0 references
56°58'9.23"N, 24°13'58.91"E
0 references
HYCOR projekta vispārējais mērķis ir atvieglot Viedās specializācijas stratēģijas (3S) prioritāšu īstenošanu Latvijā, tādējādi attīstot valsts pētniecības potenciālu, stiprinot uz zināšanām balstītu sabiedrību un veicinot tautsaimniecības konkurences priekšrocības un pastiprinot starptautisko sadarbību pētniecības jomā.Specifiskais mērķis ir veicināt izelpas gaistošā marķiera koncepciju kolorektālā vēža (KRV) skrīningā, veicinot jauna hibrīda analizatora izstrādāšanu šim mērķim. Projekta pamatojums ir balstīts uz grupas iepriekšējo pieredzi, kā arī jauniem tehnoloģiskiem sasniegumiem gaistošo organisko savienojumu (GOS) noteikšanā cilvēka izelpā, lai atklātu vēzi. Ir paredzams, ka hibrīda analizatora koncepcija dos labumu, apvienojot metālu oksīdu (MOX) un infrasarkanā spektra (IS) sensoru iegūtos datus. Šis pētījums būs pirmais, kas globāli risinās šo koncepciju KRV noteikšanā. Turklāt, tiks izmantotas tradicionālās metodes, jo īpaši gāzu hromatogrāfija kopā ar masspektrometriju (GC-MS), lai izpētītu no vēža audiem emitēto GOS bioloģisko nozīmi, kas palīdzēs turpināt attīstīt hibrīdu uztveršanas pieeju.Lai sasniegtu projekta mērķus, ir izvirzīti četri specifiski pētniecības mērķi:1. specifiskais atbalsta mērķis (SAM1). Identificēt KRV audu emitētos GOS un salīdzināt tos ar vēzi neskarto audu emitētajiem GOS (ex vivo ķirurģiskais materiāls), izmantojot GC-MS.2. specifiskais atbalsta mērķis (SAM2). Identificēt GOS, kas atšķiras KRV pacientu un kontroles pacientu izelpā (izmantojot GC-MS), kā arī salīdzināt KRV pacientu izelpas ķīmisko signatūru ar vēža audu ķīmisko signatūru.3. specifiskais atbalsta mērķis (SAM3). Novērtēt sensoru kopas veiktspēju hibrīdā analizatorā un konkrētu sensoru veiktspēju KRV noteikšanai; izstrādāt un validēt matemātisku modeli KRV noteikšanai.4. specifiskais atbalsta mērķis (SAM4). Validēt hibrīda analizatoru reāllaika KRV skrīninga veikšanas vietās, t. i., salīdzinājumā ar vispārpieņemto KRV skrīninga metodi – slēpto asiņu noteikšanu izkārnījumos.Projekts tiks realizēts, kopumā īstenojot 6 savstarpēji saistītas darba pakotnes (DP), katra no kurām tiks sadalīta detalizētos pētniecības uzdevumos: DP1. Būtiski sagatavošanas darbi.DP2. Konkrētu GOS identifikācija KRV audu ķirurģiskajā materiālā.DP3. Konkrētu GOS identifikācija KRV pacientu izelpā, pamatojoties uz GC-MS rezultātiem.DP4. Izelpas GOS noteikšana un primārās validācijas pētījums ar hibrīda analizatoru.DP5. Sekundārais validācijas pētījums vispārīgās KRV skrīninga veikšanas vietās.DP6. Zināšanu apmaiņa, saziņa un izplatīšana.Šī projekta zinātniskie rezultāti sniegs jaunas zināšanas par hibrīda izelpas analizatora iespējamo pielietojumu KRV skrīningā, iespējams, aizstājot pašreizējās skrīninga modalitātes populācijas skrīninga programmās. Kaut gan lielākajā daļā Eiropas Savienības (ES) valstu šobrīd ir pieejamas skrīninga programmas, pašlaik izmantotie testi joprojām nav ideāli. Tāpēc iegūtie rezultāti būtu svarīgi klīniskajai praksei Latvijā vai globāli – valstīs ar vidējo vai augsto KRV slogu.To plānots paveikt rūpniecisko pētījumu projektā (TRL 3-4), un plānotās aktivitātes nav saistītas ar komercdarbību. Saskaņā ar Ekonomiskās sadarbības un attīstības organizācijas (OECD) klasifikāciju projekts atbilst veselības zinātnei (3.3, Pētniecības un attīstības klasifikācijas jomas, Frascati rokasgrāmata, 2015).Pētījuma rezultātā tiks izstrādāta jauna medicīniskā tehnoloģija ar augstu pievienoto vērtību, tādējādi sekmējot Latvijas RIS3 stratēģijas 1. izaugsmes prioritātes īstenošanu, jo īpaši prioritāti: “Zināšanu ietilpīga medicīna, tostarp biomedicīna, medicīnas tehnoloģijas.”Projekta mērķis ir izstrādāt principiāli jaunu pieeju vēža noteikšanai, veicot izelpotā gaisa analīzi. Pamatojoties uz GOS rezultātiem tiks izstrādāts matemātisks modelis; tiks veikta hibrīda analizatora validācija. Tiks izmantotas iepriekš iegūtās zināšanas.Ir plānots sagatavot un publicēt 3 oriģinālas zinātniskās publikācijas zinātniski recenzētos žurnālos, 2 no tām – žurnālos ar citējamības rādītāju > 50% no vidējā rādītāja attiecīgajā jomā. Rezultātus paredzēts izplatīt 5 tēzēs. Šajā projektā tiks nodarbināti vismaz 2 studenti, tajā skaitā 1 doktorantūras students; pēc projekta pabeigšanas tiks saglabātas 2 jauno zinātnieku darba vietas.Projekts tiks realizēts Latvijas Universitātes (LU) vadībā partnerībā ar komercsabiedrību – Liepājas reģionālo slimnīcu (slimnīcu).Projekta kopējais budžets ir 540 540.00 EUR, no kuriem 92,5% - 499 999.50 EUR ir valsts finansējums (ieskaitot publisko finansējumu no ERAF – 82,29% 444 810.37 EUR, no Latvijas valdības – 10.21% - 55 189.13 EUR) un 7,50% 40 540.50 EUR no privātā sektora. Projekta ilgums – 29 mēneši (2021.gada jūlijs – 2023.gada novembris).Projekta vidusposms - 2022. gada novembris.Projekta īstenošanas jomai (tautsaimniecības nozarei) un sagaidāmajiem rezultātiem atbilstošais saimnieciskās darbības statistiskās klasifikācijas NACE kods - 86 "Veselības aizsardzība"Atslēga (Latvian)
0 references
The overall objective of the HYCOR project is to facilitate implementation of the Smart Specialisation Strategy (3S) priorities in Latvia, thus developing the research potential of the country, strengthening the knowledge-based society and promoting the competitive advantage of the economy and strengthening international cooperation in the field of research.Special objective is to promote the concept of expiratory volatile marker in colorectal cancer (CRC) screening by promoting the development of a new hybrid analyser for this purpose. The rationale for the project is based on the group’s previous experience as well as new technological advances in the determination of volatile organic compounds (VOC) in human exhalation to detect cancer. The hybrid analyser concept is expected to benefit from the pooling of metal oxide (MOX) and infrared spectrum (IS) sensors. This study will be the first to address this concept globally in the definition of the CRC. In addition, traditional methods, in particular gas chromatography together with mass spectrometry (GC-MS), will be used to explore the biological relevance of VOCs emitted from cancer tissues, which will help to further develop a hybrid capture approach.Four specific research objectives have been set to achieve the project’s objectives:1 Specific Support Objective (SAM1). Identify VOCs emitted by CRC tissues and compare them with VOC emitted by non-cancerous tissues (ex vivo surgical material) using GC-MS.2 Specific Support Objective (SAM2). Identify VOCs that differ between CRC patients and control patients in exhalation (using GC-MS) and compare expiratory chemical signage of CRC patients with cancer tissue chemical signage.3 Specific Support Objective (SAM3). Assess the performance of a set of sensors in a hybrid analyser and the performance of specific sensors for the determination of CRCs; Develop and validate a mathematical model for the determination of CRV.4 specific support objective (SAM4). Validate the hybrid analyser at real-time CRC screening sites, i.e. compared to the conventional CRC screening method – faecal occult blood detection.The project will be realised by implementing a total of 6 interconnected work packages (DPs), each of which will be divided into detailed research tasks: OP1. Significant preparatory work.DP2. Identification of specific VOC in CRC tissue surgical material.DP3. Identification of specific VOCs in exhalation of CRC patients based on GC-MS results.DP4. Expiratory VOC assay and primary validation study with hybrid analyser.DP5. Secondary validation study at general CRC screening sites.DP6. Knowledge sharing, communication and dissemination.Scientific results of this project will provide new knowledge about the possible use of a hybrid expiratory analyser in CRC screening, possibly replacing the current phases of screening in population screening programmes. Although screening programmes are currently available in most European Union (EU) countries, the tests currently used are still not ideal. Therefore, the obtained results would be important for clinical practice in Latvia or globally – in countries with average or high CRC burden.It is planned to do this in the industrial research project (TRL 3-4), and the planned activities are not related to commercial activities. According to the classification of the Organisation for Economic Cooperation and Development (OECD), the project complies with the health science (3.3, Research and Development Classification, Frascati Manual, 2015).As a result of the study, a new medical technology with high added value will be developed, thus contributing to the implementation of the 1st growth priority of the Latvian RIS3 strategy, especially priority: “Knowledge-intensive medicine, including biomedicine, medical technologies.”The aim of the project is to develop a fundamentally new approach to cancer detection through breath analysis. A mathematical model will be developed based on VOC results; The hybrid analyser will be validated. It is planned to prepare and publish 3 original scientific publications in peer-reviewed journals, 2 of them – in journals with a citation rate > 50 % of the average in the respective field. The results are expected to be distributed in 5 theses. This project will employ at least 2 students, including 1 doctoral students; After the completion of the project, 2 young scientists will be saved.The project will be implemented under the guidance of the University of Latvia (LU) in partnership with Liepaja Regional Hospital (hospital).The total budget of the project is EUR 540540.00, of which 92.5 % – EUR 499999.50 is state funding (including public funding from ERDF – 82.29 % EUR 444810.37, Latvian government – 10.21 % – EUR 55189.13) and 7.50 % EUR 40540.50 from the private sector. (English)
15 July 2021
0 references
Gaiļezera iela 1, Rīga, LV-1079
0 references
Slimnīcas iela 25, Liepāja, LV-3414
0 references
Identifiers
1.1.1.1/20/A/035
0 references